NASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $4.22 -0.03 (-0.71%) Closing price 04:00 PM EasternExtended Trading$4.30 +0.08 (+1.90%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Corbus Pharmaceuticals Stock (NASDAQ:CRBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corbus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.10▼$4.3450-Day Range$3.99▼$11.4852-Week Range$3.87▼$17.24Volume1.48 million shsAverage Volume863,598 shsMarket Capitalization$78.79 millionP/E RatioN/ADividend YieldN/APrice Target$39.57Consensus RatingModerate Buy Company Overview Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers. The company has also pursued antibody-drug conjugate programs, including CRB-701, which is designed to target Nectin-4, a protein expressed by various solid tumors. Founded in 2009 and based in Norwood, Massachusetts, Corbus previously developed lenabasum, an investigational cannabinoid receptor type 2 agonist for inflammatory and fibrotic diseases. The company later shifted its primary strategic focus toward oncology. Corbus is led by Chief Executive Officer Yuval Cohen, Ph.D., who has been associated with the company since its early development.AI Generated. May Contain Errors. Read More Corbus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreCRBP MarketRank™: 3.74644978053 of 5 starsCorbus Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 160th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCorbus Pharmaceuticals has a consensus price target of $39.57, representing about 837.7% upside from its current price of $4.22.Amount of Analyst CoverageCorbus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Corbus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($5.62) to ($6.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Corbus Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.07% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 2.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently decreased by 11.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.71 News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat Follows2 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have sold 1,130.13% more of their company's stock than they have bought. Specifically, they have bought $25,038.00 in company stock and sold $308,000.00 in company stock.Percentage Held by Insiders3.50% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBP Stock News HeadlinesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Has Consensus Target Price of $39.57 According to AnalystsOctober 25, 2026 | americanbankingnews.comCorbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026October 22, 2026 | globenewswire.comThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former hedge fund trader Lance Ippolito says it identifies early moves and lets traders set their own risk level instead of guessing.October 29 at 1:00 AM | The TradingPub (Ad)Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed in Tempo-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerSeptember 29, 2026 | marketscreener.comMCorbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerSeptember 29, 2026 | globenewswire.comWedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)September 17, 2026 | theglobeandmail.comCorbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy TranscriptSeptember 14, 2026 | seekingalpha.comCorbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial DataSeptember 14, 2026 | finance.yahoo.comSee More Headlines CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $8.14 on January 1st, 2026. Since then, CRBP shares have decreased by 48.2% and is now trading at $4.22. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.26) by $0.55. When did Corbus Pharmaceuticals IPO? Corbus Pharmaceuticals (CRBP) raised $20 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 20,206,636 shares at a price of $1.00 per share. Who are Corbus Pharmaceuticals' major shareholders? Top institutional shareholders of Corbus Pharmaceuticals include Doliver Advisors LP (0.41%). Insiders that own company stock include Yuval Cohen, Dominic Smethurst, Sean F Moran, Nishant C Saxena, Ian Hodgson, Winston Kung, Yong Ben, Anne Altmeyer and John Kenneth Jenkins. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Aurora Cannabis (ACB), Tesla (TSLA), Alibaba Group (BABA) and Cronos Group (CRON). Company Calendar Last Earnings8/06/2026Today10/29/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, CRBP's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRBP CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees36Year Founded2009Price Target and Rating Average Price Target for Corbus Pharmaceuticals$39.57 High Price Target$53.00 Low Price Target$30.00 Potential Upside/Downside+837.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($6.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.05% Return on Assets-74.22% Debt Debt-to-Equity RatioN/A Current Ratio5.71 Quick Ratio5.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.40 per share Price / Book0.50Miscellaneous Outstanding Shares18,670,000Free Float18,018,000Market Cap$78.79 million OptionableOptionable Beta2.63 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CRBP) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
